Abstract
Registry-based epidemiologic studies suggest associations between chronic inflammatory intestinal diseases and pancreatic ductal adenocarcinoma (PDAC). As genetic susceptibility contributes to a large proportion of chronic inflammatory intestinal diseases, we hypothesize that the genomic regions surrounding established genome-wide associated variants for these chronic inflammatory diseases are associated with PDAC. We examined the association between PDAC and genomic regions (+500 kb) surrounding established common susceptibility variants for ulcerative colitis, Crohn's disease, inflammatory bowel disease, celiac disease, chronic pancreatitis, and primary sclerosing cholangitis. We analyzed summary statistics from genome-wide association studies data for 8,384 cases and 11,955 controls of European descent from two large consortium studies using the summary data-based adaptive rank truncated product method to examine the overall association of combined genomic regions for each inflammatory disease group. Combined genomic susceptibility regions for ulcerative colitis, Crohn disease, inflammatory bowel disease, and chronic pancreatitis were associated with PDAC at P values < 0.05 (0.0040, 0.0057, 0.011, and 3.4 x 10-6, respectively). After excluding the 20 PDAC susceptibility regions (+500 kb) previously identified by GWAS, the genomic regions for ulcerative colitis, Crohn disease, and inflammatory bowel disease remained associated with PDAC (P ¼ 0.0029, 0.0057, and 0.0098, respectively). Genomic regions for celiac disease (P ¼ 0.22) and primary sclerosing cholangitis (P ¼ 0.078) were not associated with PDAC. Our results support the hypothesis that genomic regions surrounding variants associated with inflammatory intestinal diseases, particularly, ulcerative colitis, Crohn disease, inflammatory bowel disease, and chronic pancreatitis are associated with PDAC.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 4004-4013 |
| Number of pages | 10 |
| Journal | Cancer research |
| Volume | 80 |
| Issue number | 18 |
| DOIs | |
| State | Published - Sep 15 2020 |
| Externally published | Yes |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Genome-wide association study data reveal genetic susceptibility to chronic inflammatory intestinal diseases and pancreatic ductal adenocarcinoma risk'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Genome-wide association study data reveal genetic susceptibility to chronic inflammatory intestinal diseases and pancreatic ductal adenocarcinoma risk. / Yuan, Fangcheng; Hung, Rayjean J.; Walsh, Naomi et al.
In: Cancer research, Vol. 80, No. 18, 15.09.2020, p. 4004-4013.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Genome-wide association study data reveal genetic susceptibility to chronic inflammatory intestinal diseases and pancreatic ductal adenocarcinoma risk
AU - Yuan, Fangcheng
AU - Hung, Rayjean J.
AU - Walsh, Naomi
AU - Zhang, Han
AU - Platz, Elizabeth A.
AU - Wheeler, William
AU - Song, Lei
AU - Arslan, Alan A.
AU - Beane Freeman, Laura E.
AU - Bracci, Paige
AU - Canzian, Federico
AU - Du, Mengmeng
AU - Gallinger, Steven
AU - Giles, Graham G.
AU - Goodman, Phyllis J.
AU - Kooperberg, Charles
AU - Le Marchand, Loic
AU - Neale, Rachel E.
AU - Rosendahl, Jonas
AU - Scelo, Ghislaine
AU - Shu, Xiao Ou
AU - Visvanathan, Kala
AU - White, Emily
AU - Zheng, Wei
AU - Albanes, Demetrius
AU - Amiano, Pilar
AU - Andreotti, Gabriella
AU - Babic, Ana
AU - Bamlet, William R.
AU - Berndt, Sonja I.
AU - Brennan, Paul
AU - Bueno-De-Mesquita, Bas
AU - Buring, Julie E.
AU - Campbell, Peter T.
AU - Chanock, Stephen J.
AU - Fuchs, Charles S.
AU - Michael Gaziano, J.
AU - Goggins, Michael G.
AU - Hackert, Thilo
AU - Hartge, Patricia
AU - Hassan, Manal M.
AU - Holly, Elizabeth A.
AU - Hoover, Robert N.
AU - Katzke, Verena
AU - Kirsten, Holger
AU - Kurtz, Robert C.
AU - Lee, I. Min
AU - Malats, Nuria
AU - Milne, Roger L.
AU - Murphy, Neil
AU - Ng, Kimmie
AU - Oberg, Ann L.
AU - Porta, Miquel
AU - Rabe, Kari G.
AU - Real, Francisco X.
AU - Rothman, Nathaniel
AU - Sesso, Howard D.
AU - Silverman, Debra T.
AU - Thompson, Ian M.
AU - Wactawski-Wende, Jean
AU - Wang, Xiaoliang
AU - Wentzensen, Nicolas
AU - Wilkens, Lynne R.
AU - Yu, Herbert
AU - Zeleniuch-Jacquotte, Anne
AU - Shi, Jianxin
AU - Duell, Eric J.
AU - Amundadottir, Laufey T.
AU - Li, Donghui
AU - Petersen, Gloria M.
AU - Wolpin, Brian M.
AU - Risch, Harvey A.
AU - Yu, Kai
AU - Klein, Alison P.
AU - Stolzenberg-Solomon, Rachael
N1 - Funding Information: Research Council of Australia (NHMRC; grant number: 442302). R.E. Neale is supported by a NHMRC Senior Research Fellowship (#1060183). The UCSF pancreas study was supported by NIH-NCI grants (R01CA1009767, R01CA109767-S1, and R01CA059706) and the Joan Rombauer Pancreatic Cancer Fund. Collection of cancer incidence data was supported by the California Department of Public Health as part of the statewide cancer reporting program; the NCI's SEER Program under contract HSN261201000140C awarded to CPIC; and the CDC's National Program of Cancer Registries, under agreement #U58DP003862-01 awarded to the California Department of Public Health. The Yale (CT) pancreas cancer study was supported by NCI at the NIH (grant number 5R01CA098870). The cooperation of 30 Connecticut hospitals, including Stamford Hospital, in allowing patient access, is gratefully acknowledged. The Connecticut Pancreas Cancer Study was approved by the State of Connecticut Department of Public Health Human Investigation Committee. Certain data used in that study were obtained from the Connecticut Tumor Registry in the Connecticut Department of Public Health. The authors assume full responsibility for analyses and interpretation of these data. Studies included in PANDoRA were partly funded by: the Czech Science Foundation (no. P301/12/1734), the Internal Grant Agency of the Czech Ministry of Health (IGA NT 13 263); the Baden-Wuu€rttemberg State Ministry of Research, Science and Arts (Prof. H. Brenner), the Heidelberger EPZ-Pancobank (Prof. M.W. Buu€chler and team: Prof. T. Hackert, Dr. N.A. Giese, Dr. Ch. Tjaden, E. Soyka, M. Meinhardt; Heidelberger Stiftung Chirurgie and BMBF grant 01GS08114), the BMBH (Prof. P. Schirmacher; BMBF grant 01EY1101), the “5 ⨯ 1000” voluntary contribution of the Italian Government, the Italian Ministry of Health (RC1203GA57, RC1303GA53, RC1303GA54, RC1303GA50), the Italian Association for Research on Cancer (Prof. A. Scarpa; AIRC n. 12182), the Italian Ministry of Research (Prof. A. Scarpa; FIRB - RBAP10AHJB), the Italian FIMP-Ministry of Health (Prof. A. Scarpa; 12 CUP_J33G13000210001), and by the National Institute for Health Research Liverpool Pancreas Biomedical Research Unit, UK. We would like to acknowledge the contribution of Dr. Frederike Dijk and Prof. Oliver Busch (Academic Medical Center, Amsterdam, the Netherlands). Assistance with genotype data quality control was provided by Cecelia Laurie and Cathy Laurie at University of Washington Genetic Analysis Center. The American Cancer Society funds the creation, maintenance, and updating of the Cancer Prevention Study-II cohort. The authors express sincere appreciation to all Cancer Prevention Study-II participants, and to each member of the study and biospecimen management group. The authors would like to acknowledge the contribution to this study from central cancer registries supported through the Centers for Disease Control and Prevention's National Program of Cancer Registries and cancer registries supported by the NCI's Surveillance Epidemiology and End Results Program. Cancer incidence data for CLUE were provided by the Maryland Cancer Registry, Center for Cancer Surveillance and Control, Department of Health and Mental Hygiene (Baltimore, MD; http://phpa.dhmh.maryland.gov/ cancer; 410-767-4055). We acknowledge the State of Maryland, the Maryland Cigarette Restitution Fund, and the National Program of Cancer Registries of the Centers for Disease Control and Prevention for the funds that support the collection and availability of the cancer registry data.” We thank Kathy J. Helzlsouer for her contribution in CLUE. We also thank all the CLUE participants. The Melbourne Collaborative Cohort Study (MCCS) cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further augmented by Australian National Health and Medical Research Council grants 209057, 396414, and 1074383 and by infrastructure provided by Cancer Council Victoria. Cases and their vital status Funding Information: E.A. Platz reports grants from NCI during the conduct of the study; personal fees from Kaiser Permanente Northern California, Division of Research (scientific advisory committee) outside the submitted work. P. Bracci reports grants from NIH/NCI (data contributed were collected under an NCI-funded study) during the conduct of the study. M. Du reports grants from NCI, Geoffrey Beene Foundation, Arnold and Arlene Goldstein Family Foundation, and Society of MSKCC during the conduct of the study. G.G. Giles reports grants from National Health and Medical Research Council during the conduct of the study. R.E. Neale reports grants from National Health and Medical Research Council during the conduct of the study. P. Brennan reports grants from NCI (R03 CA123546-02) during the conduct of the study. J.E. Buring reports grants from NIH during the conduct of the study. C.S. Fuchs reports personal fees from Agios, Amylin Pharma, Bain Capital, CytomX Therapeutics, Daiichi-Sankyo, Eli Lilly, Entrinsic Health, Evolveimmune Funding Information: This research is supported by the Intramural Research Program, Division of Cancer Epidemiology and Genetics, NCI, NIH. We thank Laurie Burdett, Aurelie Vogt, Belynda Hicks, Amy Hutchinson, Meredith Yeager, and other staff at the NCI's Division of Epidemiology and Genetics (DECG) Cancer Genomics Research Laboratory (CGR) for GWAS genotyping. The IARC/Central Europe study was supported by a grant from the NCI at the NIH (R03 CA123546-02) and grants from the Ministry of Health of the Czech Republic (NR 9029-4/2006, NR9422-3, NR9998-3, MH CZ-DRO-MMCI 00209805). The work at Johns Hopkins University was supported by the NCI grants P50CA062924, R01CA97075, and P30 CA006973. Additional support was provided by the Lustgarten Foundation, Susan Wojcicki and Dennis Troper, and the Sol Goldman Pancreas Cancer Research Center. This work was supported by RO1 CA154823 and federal funds from the NCI, NIH under contract number HHSN261200800001E. The Mayo Clinic Biospecimen Resource for Pancreas Research study is supported by the Mayo Clinic SPORE in Pancreatic Cancer (P50 CA102701). The Memorial Sloan Kettering Cancer Center Pancreatic Tumor Registry is supported by P30CA008748, the Geoffrey Beene Foundation, the Arnold and Arlene Goldstein Family Foundation, and the Society of MSKCC. We acknowledge the contribution of Dr. Irene Orlow to the study. The Queensland Pancreatic Cancer Study was supported by a grant from the National Health and Medical Research Council of Australia (NHMRC; grant number: 442302). R.E. Neale is supported by a NHMRC Senior Research Fellowship (#1060183). The UCSF pancreas study was supported by NIH-NCI grants (R01CA1009767, R01CA109767-S1, and R01CA059706) and the Joan Rombauer Pancreatic Cancer Fund. Collection of cancer incidence data was supported by the California Department of Public Health as part of the statewide cancer reporting program; the NCI's SEER Program under contract HSN261201000140C awarded to CPIC; and the CDC's National Program of Cancer Registries, under agreement #U58DP003862-01 awarded to the California Department of Public Health. The Yale (CT) pancreas cancer study was supported by NCI at the NIH (grant number 5R01CA098870). The cooperation of 30 Connecticut hospitals, including Stamford Hospital, in allowing patient access, is gratefully acknowledged. The Connecticut Pancreas Cancer Study was approved by the State of Connecticut Department of Public Health Human Investigation Committee. Certain data used in that study were obtained from the Connecticut Tumor Registry in the Connecticut Department of Public Health. The authors assume full responsibility for analyses and interpretation of these data. Studies included in PANDoRA were partly funded by: the Czech Science Foundation (no. P301/12/1734), the Internal Grant Agency of the Czech Ministry of Health (IGA NT 13 263); the Baden-Wuurttemberg State Ministry of Research, Science and Arts (Prof. H. Brenner), the Heidelberger EPZ-Pancobank (Prof. M.W. Buuchler and team: Prof. T. Hackert, Dr. N.A. Giese, Dr. Ch. Tjaden, E. Soyka, M. Meinhardt; Heidelberger Stiftung Chirurgie and BMBF grant 01GS08114), the BMBH (Prof. P. Schirmacher; BMBF grant 01EY1101), the ?5 x 1000? voluntary contribution of the Italian Government, the Italian Ministry of Health (RC1203GA57, RC1303GA53, RC1303GA54, RC1303GA50), the Italian Association for Research on Cancer (Prof. A. Scarpa; AIRC n. 12182), the Italian Ministry of Research (Prof. A. Scarpa; FIRB - RBAP10AHJB), the Italian FIMP-Ministry of Health (Prof. A. Scarpa; 12 CUP_J33G13000210001), and by the National Institute for Health Research Liverpool Pancreas Biomedical Research Unit, UK. We would like to acknowledge the contribution of Dr. Frederike Dijk and Prof. Oliver Busch (Academic Medical Center, Amsterdam, the Netherlands). Assistance with genotype data quality control was provided by Cecelia Laurie and Cathy Laurie at University of Washington Genetic Analysis Center. The American Cancer Society funds the creation, maintenance, and updating of the Cancer Prevention Study-II cohort. The authors express sincere appreciation to all Cancer Prevention Study-II participants, and to each member of the study and biospecimen management group. The authors would like to acknowledge the contribution to this study from central cancer registries supported through the Centers for Disease Control and Prevention's National Program of Cancer Registries and cancer registries supported by the NCI's Surveillance Epidemiology and End Results Program. Cancer incidence data for CLUE were provided by the Maryland Cancer Registry, Center for Cancer Surveillance and Control, Department of Health and Mental Hygiene (Baltimore, MD; http://phpa.dhmh.Maryland.gov/ cancer; 410-767-4055). We acknowledge the State of Maryland, the Maryland Cigarette Restitution Fund, and the National Program of Cancer Registries of the Centers for Disease Control and Prevention for the funds that support the collection and availability of the cancer registry data.? We thank Kathy J. Helzlsouer for her contribution in CLUE. We also thank all the CLUE participants. The Melbourne Collaborative Cohort Study (MCCS) cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further augmented by Australian National Health and Medical Research Council grants 209057, 396414, and 1074383 and by infrastructure provided by Cancer Council Victoria. Cases and their vital status were ascertained through the Victorian Cancer Registry and the Australian Institute of Health and Welfare, including the National Death Index and the Australian Cancer Database. The NYU Women's Health Study (AZJ and AAA) was funded by NIH UM1 CA182934 and center grants P30 CA016087 and P30 ES000260. The PANKRAS II Study in Spain was supported by research grants from Instituto de Salud Carlos III-FEDER, Spain; Fondo de Investigaciones Sanitarias (FIS; #PI13/00082 and #PI15/01573) and Red Tematica de Investigacion Cooperativa en Cancer, Spain (#RD12/0036/0050); and European Cooperation in Science and Technology (COST Action #BM1204: EU_Pancreas), Ministerio de Ciencia y Tecnolog?a (CICYT SAF 2000-0097), Fondo de Investigacion Sanitaria (95/0017), Madrid, Spain; Generalitat de Catalunya (CIRIT - SGR); 'Red tematica de investigacion cooperativa de centros en Cancer' (C03/10), 'Red tematica de investigacion cooperativa de centros en Epidemiolog?a y salud publica' (C03/09), and CIBER de Epidemiolog?a (CIBERESP), Madrid. The Physicians' Health Study was supported by research grants CA-097193, CA-34944, CA-40360, HL-26490, and HL-34595 from the NIH. The Women's Health Study was supported by research grants CA-047988, CA-182913, HL-043851, HL-080467, and HL-099355 from the NIH. Health Professionals Followup Study is supported by NIH grant UM1 CA167552 from the NCI. Nurses' Health Study is supported by NIH grants UM1 CA186107, P01 CA87969, and R01 CA49449 from the NCI. Multiethnic Cohort Study was supported by NIH grants CA63464, CA54281, CA098758, CA132839 and CA164973 from the NCI. Additional support from the Hale Center for Pancreatic Cancer Research, U01 CA21017 from the NCI, and the United States Department of Defense CA130288, Lustgarten Foundation, Pancreatic Cancer Action Network, Noble Effort Fund, Peter R. Leavitt Family Fund, Wexler Family Fund, and Promises for Purple (to B.M. Wolpin); Broman Family Fund for Pancreatic Cancer Research (to K. Ng); and K07 CA222159 from the NCI, and Bob Parsons Fellowship (to A. Babic). The WHI program is funded by the National Heart, Lung, and Blood Institute, NIH, U.S. Department of Health and Human Services through contracts HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C. The authors thank the WHI investigators and staff for their dedication, and the study participants for making the program possible. A full listing of WHI investigators can be found at: http://www.whi.org/researchers/Documents%20%20Write%20a% 20Paper/WHI%20Investigator%20Long%20List.pdf. SELECT is funded by the NCI of the NIH under Award Numbers U10 CA37429 (to C.D. Blanke), and UM1 CA182883 (to C.M. Tangen/I.M. Thompson). The authors thank the site investigators and staff and, most importantly, the participants from SELECT who donated their time to this trial. This study utilized the high-performance computational capabilities of the Biowulf Linux cluster at the NIH (https://hpc.nih.gov/systems/). The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the NIH, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. The data used for the analyses described in this manuscript were obtained from the GTEx Portal on September 24, 2019. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Received February 19, 2020; revised April 27, 2020; accepted July 2, 2020; published first July 8, 2020. Funding Information: Therapeutics, Genentech, Merck, Taiho, and Unum Therapeutics outside the submitted work; in addition, C.S. Fuchs also serves as a Director for CytomX Therapeutics, owns unexercised stock options for CytomX and Entrinsic Health, is a cofounder of Evolveimmune Therapeutics, and has equity in this private company. C.S. Fuchs has also provided expert testimony for Amylin Pharmaceuticals and Eli Lilly. H. Kirsten reports grants from LIFE [H. Kirsten is funded by the Leipzig Research Center for Civilization Diseases (LIFE); LIFE is an organizational unit affiliated to the Medical Faculty of the University of Leipzig. LIFE is funded by means of the European Union, by the European Regional Development Fund (ERDF) and by funds of the Free State of Saxony within the framework of the excellence initiative] during the conduct of the study. I.-M. Lee reports grants from the NIH during the conduct of the study. R. Milne reports grants from NHMRC during the conduct of the study. K. Ng reports grants from Celgene, Revolution Medicines, Evergrande Group, Genentech, Gilead Sciences, Trovagene, grants and personal fees from Tarrex Biopharma, and personal fees from Bayer, Seattle Genetics, and Array Biopharma outside the submitted work. A.L. Oberg reports grants from NIH during the conduct of the study. J. Wactawski-Wende reports grants from NIH/NHLBI (funding for WHI) during the conduct of the study. A. Zeleniuch-Jacquotte reports grants from NIH/NCI during the conduct of the study. B.M. Wolpin reports grants and personal fees from Celgene and Eli Lilly, and personal fees from GRAIL and BiolineRx outside the submitted work. H.A. Risch reports grants from NIH during the conduct of the study. No potential conflicts of interest were disclosed by the other authors. Funding Information: This research is supported by the Intramural Research Program, Division of Cancer Epidemiology and Genetics, NCI, NIH. We thank Laurie Burdett, Aurelie Vogt, Belynda Hicks, Amy Hutchinson, Meredith Yeager, and other staff at the NCI's Division of Epidemiology and Genetics (DECG) Cancer Genomics Research Laboratory (CGR) for GWAS genotyping. The IARC/Central Europe study was supported by a grant from the NCI at the NIH (R03 CA123546-02) and grants from the Ministry of Health of the Czech Republic (NR 9029-4/2006, NR9422-3, NR9998-3, MH CZ-DRO-MMCI 00209805). The work at Johns Hopkins University was supported by the NCI grants P50CA062924, R01CA97075, and P30 CA006973. Additional support was provided by the Lustgarten Foundation, Susan Wojcicki and Dennis Troper, and the Sol Goldman Pancreas Cancer Research Center. This work was supported by RO1 CA154823 and federal funds from the NCI, NIH under contract number HHSN261200800001E. The Mayo Clinic Biospecimen Resource for Pancreas Research study is supported by the Mayo Clinic SPORE in Pancreatic Cancer (P50 CA102701). The Memorial Sloan Kettering Cancer Center Pancreatic Tumor Registry is supported by P30CA008748, the Geoffrey Beene Foundation, the Arnold and Arlene Goldstein Family Foundation, and the Society of MSKCC. We acknowledge the contribution of Dr. Irene Orlow to the study. The Queensland Pancreatic Cancer Study was supported by a grant from the National Health and Medical Publisher Copyright: © 2020 American Association for Cancer Research.
PY - 2020/9/15
Y1 - 2020/9/15
N2 - Registry-based epidemiologic studies suggest associations between chronic inflammatory intestinal diseases and pancreatic ductal adenocarcinoma (PDAC). As genetic susceptibility contributes to a large proportion of chronic inflammatory intestinal diseases, we hypothesize that the genomic regions surrounding established genome-wide associated variants for these chronic inflammatory diseases are associated with PDAC. We examined the association between PDAC and genomic regions (+500 kb) surrounding established common susceptibility variants for ulcerative colitis, Crohn's disease, inflammatory bowel disease, celiac disease, chronic pancreatitis, and primary sclerosing cholangitis. We analyzed summary statistics from genome-wide association studies data for 8,384 cases and 11,955 controls of European descent from two large consortium studies using the summary data-based adaptive rank truncated product method to examine the overall association of combined genomic regions for each inflammatory disease group. Combined genomic susceptibility regions for ulcerative colitis, Crohn disease, inflammatory bowel disease, and chronic pancreatitis were associated with PDAC at P values < 0.05 (0.0040, 0.0057, 0.011, and 3.4 x 10-6, respectively). After excluding the 20 PDAC susceptibility regions (+500 kb) previously identified by GWAS, the genomic regions for ulcerative colitis, Crohn disease, and inflammatory bowel disease remained associated with PDAC (P ¼ 0.0029, 0.0057, and 0.0098, respectively). Genomic regions for celiac disease (P ¼ 0.22) and primary sclerosing cholangitis (P ¼ 0.078) were not associated with PDAC. Our results support the hypothesis that genomic regions surrounding variants associated with inflammatory intestinal diseases, particularly, ulcerative colitis, Crohn disease, inflammatory bowel disease, and chronic pancreatitis are associated with PDAC.
AB - Registry-based epidemiologic studies suggest associations between chronic inflammatory intestinal diseases and pancreatic ductal adenocarcinoma (PDAC). As genetic susceptibility contributes to a large proportion of chronic inflammatory intestinal diseases, we hypothesize that the genomic regions surrounding established genome-wide associated variants for these chronic inflammatory diseases are associated with PDAC. We examined the association between PDAC and genomic regions (+500 kb) surrounding established common susceptibility variants for ulcerative colitis, Crohn's disease, inflammatory bowel disease, celiac disease, chronic pancreatitis, and primary sclerosing cholangitis. We analyzed summary statistics from genome-wide association studies data for 8,384 cases and 11,955 controls of European descent from two large consortium studies using the summary data-based adaptive rank truncated product method to examine the overall association of combined genomic regions for each inflammatory disease group. Combined genomic susceptibility regions for ulcerative colitis, Crohn disease, inflammatory bowel disease, and chronic pancreatitis were associated with PDAC at P values < 0.05 (0.0040, 0.0057, 0.011, and 3.4 x 10-6, respectively). After excluding the 20 PDAC susceptibility regions (+500 kb) previously identified by GWAS, the genomic regions for ulcerative colitis, Crohn disease, and inflammatory bowel disease remained associated with PDAC (P ¼ 0.0029, 0.0057, and 0.0098, respectively). Genomic regions for celiac disease (P ¼ 0.22) and primary sclerosing cholangitis (P ¼ 0.078) were not associated with PDAC. Our results support the hypothesis that genomic regions surrounding variants associated with inflammatory intestinal diseases, particularly, ulcerative colitis, Crohn disease, inflammatory bowel disease, and chronic pancreatitis are associated with PDAC.
UR - http://www.scopus.com/inward/record.url?scp=85100342501&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100342501&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-20-0447
DO - 10.1158/0008-5472.CAN-20-0447
M3 - Article
C2 - 32641412
AN - SCOPUS:85100342501
VL - 80
SP - 4004
EP - 4013
JO - Cancer Research
JF - Cancer Research
SN - 0008-5472
IS - 18
ER -